Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 …

N Gangat, O Karrar, M Iftikhar… - American journal of …, 2024 - Wiley Online Library
Venetoclax+ hypomethylating agent (Ven‐HMA) is currently the standard frontline therapy
for older/unfit patients with newly diagnosed acute myeloid leukemia (ND‐AML). Our …
被引用次数：17 相关文章

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 …

N Gangat, O Karrar, M Iftikhar… - American journal …, 2024 - pubmed.ncbi.nlm.nih.gov
Venetoclax+ hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for
older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective …

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 …

N Gangat, O Karrar, M Iftikhar… - American Journal of …, 2023 - europepmc.org
Venetoclax+ hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for
older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective …

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 …

N Gangat, O Karrar, M Iftikhar… - American journal …, 2024 - mayoclinic.elsevierpure.com
Venetoclax+ hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for
older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective …